Everolimus and early calcineurin inhibitor withdrawal: 3-year results from a randomized trial in liver transplantation

American Journal of Transplantation

Volumn 14, Issue 3, 2014, Pages 701-710

  Sterneck, M ^a   Kaiser, G M ^b   Heyne, N ^c   Richter, N ^d   Rauchfuss, F ^e   Pascher, A ^f   Schemmer, P ^g   Fischer, L ^a   Klein, C G ^b   Nadalin, S ^c   Lehner, F ^d   Settmacher, U ^e   Neuhaus, P ^f   Gotthardt, D ^g   Loss, M ^h   Ladenburger, S ⁱ   Paulus, E M ⁱ   Mertens, M ⁱ   Schlitt, H J ^h  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e JENA UNIVERSITY HOSPITAL   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^h UNIVERSITY HOSPITAL REGENSBURG   (Germany)

ⁱ NOVARTIS PHARMA GMBH   (Germany)

Author keywords

Calcineurin inhibitor; everolimus; liver transplantation; long term; withdrawal

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ADULT; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DIARRHEA; DIET; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; INCISIONAL HERNIA; KIDNEY DISEASE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT WITHDRAWAL;

CALCINEURIN INHIBITOR; EVEROLIMUS; LIVER TRANSPLANTATION; LONG-TERM; WITHDRAWAL;

ADOLESCENT; ADULT; AGED; CALCINEURIN; CYCLOSPORINE; FEASIBILITY STUDIES; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER DISEASES; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; SIROLIMUS; TIME FACTORS; WITHHOLDING TREATMENT; YOUNG ADULT;

EID: 84896694941     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12615     Document Type: Article

References (24)

1. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
2. Lamattina JC, Mezrich JD, Fernandez LA, et al. Native kidney function following liver transplantation using calcineurin inhibitors: Single-center analysis with 20 years of follow-up. Clin Transplant 2013; 27: 193-202.
3. Lee JP, Heo NJ, Joo KW, et al. Risk factors for consequent kidney impairment and differential impact of liver transplantation on renal function. Nephrol Dial Transplant 2010; 25: 2772-2785.
4. Herlenius G, Fistouris J, Olausson M, Felldin M, Bäckman L, Friman S., Early renal function post-liver transplantation is predictive of progressive chronic kidney disease. Scand J Gastroenterol 2008; 43: 344-349.
5. Garces G, Contreras G, Carvalho D, et al. Chronic kidney disease after orthotopic liver transplantation in recipients receiving tacrolimus. Clin Nephrol 2011; 75: 150-157.
6. Fabrizi F, Dixit V, Martin P, Messa P., Chronic kidney disease after liver transplantation: Recent evidence. Int J Artif Organs 2010; 33: 803-811.
7. De Simone P, Metselaar HJ, Fischer L, et al. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: A prospective, randomized, multicenter trial. Liver Transpl 2009; 15: 1262-1269.
8. Abdelmalek MF, Humar A, Stickel F, et al. Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: A randomized trial. Am J Transplant 2012; 12: 694-705.
9. Masetti M, Montalti R, Rompianesi G, et al. Early withdrawal of calcineurin inhibitors and everolimus monotherapy in de novo liver transplant recipients preserves renal function. Am J Transplant 2010; 10: 2252-2262.
10. De Simone P, Nevens F, De Carlis L, et al. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: A randomized controlled trial. Am J Transplant 2012; 12: 3008-3020.
11. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-Month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233-242.
12. Holdaas H, Rostaing L, Serõn D, et al. Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: A randomized, multicenter, 24-month study. Transplantation 2011; 92: 410-418.
13. Fischer L, Klempnauer J, Beckebaum S, et al. A randomized, controlled study to assess the conversion from calcineurin-inhibitors to everolimus after liver transplantation-PROTECT. Am J Transplant 2012; 12: 1855-1865.
14. Burra P, Senzolo M, Masier A, et al. Factors influencing renal function after liver transplantation. Results from the MOST, an international observational study. Dig Liver Dis 2009; 41: 350-356.
15. Cantarovich M, Tchervenkov J, Paraskevas S, et al. Early changes in kidney function predict long-term chronic kidney disease and mortality in patients after liver transplantation. Transplantation 2011; 92: 1358-1363.
16. Everson GT., Everolimus and mTOR inhibitors in liver transplantation: Opening the "box." Liver Transpl 2006; 12: 1571-1573.
17. Cockcroft DW, Gault MH., Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
18. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D., A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 1999; 130: 461-470.
19. Nankivell BJ, Gruenewald SM, Allen R, Chapman JR., Predicting glomerular filtration rate after kidney transplantation. Transplantation 1995; 59: 1683-1689.
20. Sanchez EQ, Melton LB, Chinnakotla S, et al. Predicting renal failure after liver transplantation from measure glomerular filtration rate: Review of up to 15 years of follow-up. Transplantation 2010; 89: 232-235.
21. Pawarode A, Fine DM, Thuluvath PJ., Independent risk factors and natural history of renal dysfunction in liver transplant recipients. Liver Transpl 2003; 9: 741-747.
22. Nashan B., Is acute rejection the key predictor for long-term outcomes after renal transplantation when comparing calcineurin inhibitors ? Transplant Rev 2009; 23: 47-52.
23. Shihab FS, Cibrik D, Chan L, et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clin Transplant 2013; 27: 217-226.
24. Vallin M, Guillaud O, Morard I, et al. Tolerability of everolimus-based immunosuppression in maintenance liver transplant recipients. Clin Transplant 2011; 25: 660-669.